Tags

Type your tag names separated by a space and hit enter

COVID-19-associated coagulopathy.
Diagnosis (Berl). 2020 Nov 18; 7(4):357-363.D

Abstract

Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19.

Authors+Show Affiliations

Italian National Blood Centre, Rome, Italy. Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy. Infection Control Committee and Antibiotic Stewardship Programme, AULSS9, Scaligera, Verona, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy.Italian National Blood Centre, Rome, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32683333

Citation

Franchini, Massimo, et al. "COVID-19-associated Coagulopathy." Diagnosis (Berlin, Germany), vol. 7, no. 4, 2020, pp. 357-363.
Franchini M, Marano G, Cruciani M, et al. COVID-19-associated coagulopathy. Diagnosis (Berl). 2020;7(4):357-363.
Franchini, M., Marano, G., Cruciani, M., Mengoli, C., Pati, I., Masiello, F., Veropalumbo, E., Pupella, S., Vaglio, S., & Liumbruno, G. M. (2020). COVID-19-associated coagulopathy. Diagnosis (Berlin, Germany), 7(4), 357-363. https://doi.org/10.1515/dx-2020-0078
Franchini M, et al. COVID-19-associated Coagulopathy. Diagnosis (Berl). 2020 Nov 18;7(4):357-363. PubMed PMID: 32683333.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19-associated coagulopathy. AU - Franchini,Massimo, AU - Marano,Giuseppe, AU - Cruciani,Mario, AU - Mengoli,Carlo, AU - Pati,Ilaria, AU - Masiello,Francesca, AU - Veropalumbo,Eva, AU - Pupella,Simonetta, AU - Vaglio,Stefania, AU - Liumbruno,Giancarlo Maria, PY - 2020/06/05/received PY - 2020/07/03/accepted PY - 2020/7/20/pubmed PY - 2020/11/27/medline PY - 2020/7/20/entrez KW - COVID-19 KW - SARS-CoV-2 KW - anticoagulant therapy KW - prophylaxis KW - thromboembolism KW - thrombosis SP - 357 EP - 363 JF - Diagnosis (Berlin, Germany) JO - Diagnosis (Berl) VL - 7 IS - 4 N2 - Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19. SN - 2194-802X UR - https://www.unboundmedicine.com/medline/citation/32683333/COVID_19_associated_coagulopathy_ L2 - https://www.degruyter.com/document/doi/10.1515/dx-2020-0078 DB - PRIME DP - Unbound Medicine ER -